Vorinostat + Pegylated Liposomal Doxorubicin (PLD), Doxil
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed Lymphomas
Conditions
Relapsed Lymphomas, Refractory Lymphomas
Trial Timeline
Jan 1, 2009 → Sep 1, 2011
NCT ID
NCT00785798About Vorinostat + Pegylated Liposomal Doxorubicin (PLD), Doxil
Vorinostat + Pegylated Liposomal Doxorubicin (PLD), Doxil is a phase 1/2 stage product being developed by Merck for Relapsed Lymphomas. The current trial status is terminated. This product is registered under clinical trial identifier NCT00785798. Target conditions include Relapsed Lymphomas, Refractory Lymphomas.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed Lymphomas were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00785798 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Relapsed Lymphomas